CompletedPhase 2

Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome

United States11 participantsStarted 2019-10-14

Plain-language summary

The purpose of this study is to better understand the utility of cannabidiol (CBD/ Epidiolex) for improving the treatment of cognitive impairments in Sturge-Weber syndrome (SWS).

Who can participate

Age range3 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Liver disease such as cirrhosis, decompensated liver disease, and chronic hepatitis (i.e. quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA)
✕. Uncontrolled diabetes as defined by fasting serum glucose greater than 1.5
✕. Active (acute or chronic) or uncontrolled severe infections
✕. Active, bleeding diathesis

What they're measuring

List Sorting Working Memory Test

Timeframe: Baseline, Follow-up (6 months)

Trial details

NCT IDNCT04447846

SponsorAnne Comi, MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-08-16

Results submitted2023-01-19

View on ClinicalTrials.gov More Sturge-Weber Syndrome trials